Behçet's syndrome
- PMID: 38402885
- DOI: 10.1016/S0140-6736(23)02629-6
Behçet's syndrome
Abstract
Behçet's syndrome is a rare, chronic multisystemic inflammatory disorder also known as the Silk Route disease due to its geographical distribution. Behçet's syndrome is a multifactorial disease and infectious, genetic, epigenetic, and immunological factors contribute to its pathogenesis. Its heterogeneous spectrum of clinical features include mucocutaneous, articular, ocular, vascular, neurological, and gastrointestinal manifestations that can present with a relapsing and remitting course. Differential diagnosis is often hampered by the non-specific clinical presentation and the absence of laboratory biomarkers or pathognomonic histological features. The therapeutic approach is tailored on the basis of patient-specific manifestations and relies on glucocorticoids, colchicine, and traditional and biological immunosuppressants. Despite progress in the knowledge and management of the disease, unmet needs in diagnostics, monitoring, prediction, and treatment personalisation challenge clinical practice, making Behçet's syndrome a complex disorder associated with an increased risk of morbidity.
Copyright © 2024 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests In the past 36 months, GE received grants and contracts from AstraZeneca; received consulting fees from SOBI, Novartis, GSK, AstraZeneca, and Vifor; received support for attending meetings and for travel by Vifor; participated on advisory boards for SOBI, Novartis, GSK, AstraZeneca, and Vifor; and is a member of the Executive Committee of the International Society for Behçet Disease. GH received grants or contracts from AbbVie, UCB Pharma, and Novartis; received consulting fees from Onko Pharmaceuticals and Pfizer; received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from Amgen, Boehringer Ingelheim, Novartis, Pfizer, UCB Pharma, and Johnson & Johnson; and received support for attending meetings and travel from Deva Pharmaceuticals. DP received honoraria for lectures by Daiichi-Sankyo, Takeda, Novo Nordisk, CSL Behring, and Sanofi, and participated in advisory boards for Daiichi-Sankyo, Takeda, Novo Nordisk, CSL Behring, and Sanofi. AB declares no competing interests.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
